Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines.
BACKGROUND
Tamoxifen, used in breast cancer treatment, competitively inhibits estrogen receptor (ER) and also demonstrates direct antiproliferative effect on cancer cells even in ER lacking cancer tissue. However its molecular mechanism of action is still unclear


METHODS
We exposed on tamoxifen 11 ovarian cancer cell lines, including well-documented platinum-sensitive and platinum-resistant ones, and studied tamoxifen-, cisplatin-sensitivity and expression of ERalpha and beta.


RESULTS
We observed: no correlation between TAM-sensitivity and ERalpha and ERbeta expressions, no correlation between TAM influence on cisplatin-sensitivity and ERalpha and ERbeta expressions, increase of ERbeta expression after TAM-exposure in 3 cell lines; decrease in the 1 line, no TAM-exposure influence on ERalpha expression and increase of 1050 for cisplatin after TAM-exposure in 5 (45%) cell lines. These results show ovarian cancer cells being affected by TAM have different platinum sensitivity


CONCLUSIONS
Our data suggests that ovarian cancer cells platinum-sensitivity are not linked with ER expressions. We claim the necessity of seeking some TAM predicting factors, using DNA microarrays.
Nowak-Markwitz
Ewa
E
Department of Gynaecological Oncology, University of Medical Science, Poznań, Poland. ewamarkwitz@poczta.fm
Maciejczyk
Adam
A
Pudełko
Marek
M
Tserenchunt
Gansukh
G
Balázs
Györffy
G
Spaczyński
Marek
M
Zabel
Maciej
M
Dietel
Manfred
M
Lage
Hermann
H
Surowiak
Pawel
P
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D004347:Drug Interactions; D019008:Drug Resistance, Neoplasm; D047628:Estrogen Receptor alpha / Q000187:drug effects / Q000378:metabolism*; D047629:Estrogen Receptor beta / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013629:Tamoxifen / Q000494:pharmacology*
D018931:Antineoplastic Agents, Hormonal; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D013629:Tamoxifen; D002945:Cisplatin